| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | January 31, 2024 |
| Accession Number: | 0001437749-24-002316 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Save time and jump to the most important pieces.
Navidea Biopharmaceuticals, Inc. ("Navidea" or the "Company") today announced that its Board of Directors has elected to extend the Company's Section 382 Rights Agreement (the "Section 382 Rights Plan"). Originally adopted on April 7, 2022, and set to expire on April 6, 2025, the plan has now been extended to April 7, 2027. The Section 382 Rights Plan is designed to safeguard Navidea's ability to utilize its net operating loss carryforwards ("NOLs") and other tax assets. As of December 31, 2024, Navidea had approximately $170 million in U.S. federal NOLs and approximately $9 million in R&D tax credits that may be used to offset future taxable income. However, these valuable tax attributes
Navidea Biopharmaceuticals, Inc. has completed an exploratory analysis of its Rheumatoid Arthritis Program Navidea Biopharmaceuticals, Inc. (OTC:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced disappointing results of an exploratory analysis conducted on the Company's pivotal NAV3-33 clinical trial titled "Evaluation of Tc 99m Tilmanocept Imaging for the Early Prediction of Anti-TNFα Therapy Response in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA)" (ClinicalTrials.gov Identifier: NCT05246280) the "RA Trial." The purpose of the exploratory analysis was to optimize th
Navidea Biopharmaceucitals, Inc. will present two proposals for vote in a virtual special meeting of shareholders to be held on July 8, 2024 Navidea Biopharmaceuticals, Inc. (OTC:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will be hosting a virtual meeting of its stockholders at 1pm ET on Monday, July 8th, 2024. The purpose of the special meeting is to consider and vote upon (i) an amendment to the Company's certificate of incorporation to allow stockholders to act by written consent, and (ii) an amendment to the Company's certificate of incorporation to implement a reverse stock
SC 13D/A - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Subject)
SC 13D/A - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Subject)
SC 13D/A - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Subject)
4 - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Issuer)
4 - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Issuer)
4 - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Issuer)
EFFECT - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Filer)
EFFECT - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Filer)
EFFECT - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Filer)
Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the appointment of Joshua ("Josh") Wilson to its Board of Directors, effective September 30, 2022, with a term ending concurrently with the Company's 2024 annual stockholders' meeting. Mr. Wilson is a seasoned banking and finance executive with more than 23 years of financial services and family office experience. During his career, Mr. Wilson focused his efforts on raising capital and streamlining company operations for profit and non-profit entities, raising more than $500 million. Currently, Mr. Wilso
Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the resignation of Jed A. Latkin as Chief Executive Officer, Chief Financial Officer and Chief Operating Officer of the Company, and as a member of the Board of Directors of the Company, effective October 24, 2021. Mr. Latkin and the Company are discussing the terms of a severance agreement pursuant to his employment contract. An Office of the CEO including three members of the Company's Board of Directors has been established to lead the Company on an interim basis while the next Chief Executive Officer
Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the appointment of Thomas Forest Farb-Horch and Agnieszka Winkler to its Board of Directors, effective October 7, 2021, each with a three-year term ending concurrently with the Company's 2024 annual stockholders' meeting. Thomas Forest Farb-Horch has over three decades of experience as an investor in and senior executive of numerous life science and information technology companies both in the U.S. and internationally. Mr. Farb has served as the Chief Executive Officer, President, co-founder and director
Navidea Biopharmaceuticals, Inc. ("Navidea" or the "Company") today announced that its Board of Directors has elected to extend the Company's Section 382 Rights Agreement (the "Section 382 Rights Plan"). Originally adopted on April 7, 2022, and set to expire on April 6, 2025, the plan has now been extended to April 7, 2027. The Section 382 Rights Plan is designed to safeguard Navidea's ability to utilize its net operating loss carryforwards ("NOLs") and other tax assets. As of December 31, 2024, Navidea had approximately $170 million in U.S. federal NOLs and approximately $9 million in R&D tax credits that may be used to offset future taxable income. However, these valuable tax attributes
Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series K Preferred Stock, par value $0.001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on June 27, 2023. The shares of Series K Preferred Stock will be distributed to such recipients at 5:00 p.m. Eastern Time on June 27, 2023. The outstanding shares of Series K Preferred Stock will vote together with the outstanding shares of the Company's
The company introduces Fix, Fund, Propel approach to further focus on strategic objectives; will publish financial and corporate development highlights via press release in lieu of conference call and webcast for Q1 2023 results. Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the introduction of a Fix, Fund, Propel approach to driving the Company's strategy forward; The Company will issue a press release detailing financial highlights and corporate developments in lieu of hosting conference call and webcast for the first quarter ended March 31st, 20